Literature DB >> 26906637

Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.

Kendra R Vann1, Yavuz Ergün2, Sevil Zencir3, Serkan Oncuoglu2, Neil Osheroff4, Zeki Topcu5.   

Abstract

Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity. Unfortunately, this compound displays a number of adverse properties. Therefore, to investigate new ellipticine-based compounds for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivatives, N-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2). As determined by DNA decatenation and cleavage assays, ET-1 and ET-2 act as catalytic inhibitors of human topoisomerase IIα and are both more potent than the parent compound. Neither compound impairs the ability of the type II enzyme to bind its DNA substrate. Finally, the potency of ET-1 and ET-2 as catalytic inhibitors of topoisomerase IIα appears to be related to their ability to intercalate into the double helix.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer drugs; Catalytic inhibitor; DNA cleavage; DNA intercalation; DNA topoisomerase IIα; Ellipticine derivatives

Mesh:

Substances:

Year:  2016        PMID: 26906637      PMCID: PMC4785065          DOI: 10.1016/j.bmcl.2016.02.034

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  37 in total

1.  Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation.

Authors:  H Wang; Y Mao; A Y Chen; N Zhou; E J LaVoie; L F Liu
Journal:  Biochemistry       Date:  2001-03-20       Impact factor: 3.162

Review 2.  Extending nature's leads: the anticancer agent ellipticine.

Authors:  Nichola C Garbett; David E Graves
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-03

3.  Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons.

Authors:  Adam C Ketron; Neil Osheroff
Journal:  Phytochem Rev       Date:  2014-03-01       Impact factor: 5.374

Review 4.  All tangled up: how cells direct, manage and exploit topoisomerase function.

Authors:  Seychelle M Vos; Elsa M Tretter; Bryan H Schmidt; James M Berger
Journal:  Nat Rev Mol Cell Biol       Date:  2011-11-23       Impact factor: 94.444

5.  Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.

Authors:  S D Cline; T L Macdonald; N Osheroff
Journal:  Biochemistry       Date:  1997-10-21       Impact factor: 3.162

6.  Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.

Authors:  E Multon; J F Riou; D LeFevre; J C Ahomadegbe; G Riou
Journal:  Biochem Pharmacol       Date:  1989-07-01       Impact factor: 5.858

7.  Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule.

Authors:  J Kattan; M Durand; J P Droz; M Mahjoubi; J P Marino; M Azab
Journal:  Am J Clin Oncol       Date:  1994-06       Impact factor: 2.339

8.  Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement.

Authors:  Omari J Bandele; Sara J Clawson; Neil Osheroff
Journal:  Chem Res Toxicol       Date:  2008-05-08       Impact factor: 3.739

Review 9.  The why and how of DNA unlinking.

Authors:  Zhirong Liu; Richard W Deibler; Hue Sun Chan; Lynn Zechiedrich
Journal:  Nucleic Acids Res       Date:  2009-02       Impact factor: 16.971

10.  Anticancer and multidrug resistance-reversal effects of solanidine analogs synthetized from pregnadienolone acetate.

Authors:  István Zupkó; Judit Molnár; Borbála Réthy; Renáta Minorics; Eva Frank; János Wölfling; Joseph Molnár; Imre Ocsovszki; Zeki Topcu; Tamás Bitó; László G Puskás
Journal:  Molecules       Date:  2014-02-17       Impact factor: 4.411

View more
  10 in total

1.  Acridine Based N-Acylhydrazone Derivatives as Potential Anticancer Agents: Synthesis, Characterization and ctDNA/HSA Spectroscopic Binding Properties.

Authors:  Mária Vilková; Monika Hudáčová; Nikola Palušeková; Rastislav Jendželovský; Miroslav Almáši; Tibor Béres; Peter Fedoročko; Mária Kožurková
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

2.  Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.

Authors:  Jissy A Kuriappan; Neil Osheroff; Marco De Vivo
Journal:  J Chem Inf Model       Date:  2019-09-09       Impact factor: 4.956

3.  Repurposing Ellipticine Hydrochloride to Combat Colistin-Resistant Extraintestinal Pathogenic E. coli (ExPEC).

Authors:  Hao Lu; Manli Liu; Wenjia Lu; Chenchen Wang; Gaoyan Wang; Wenqi Dong; Xiangru Wang; Huanchun Chen; Chen Tan
Journal:  Front Microbiol       Date:  2020-05-25       Impact factor: 5.640

4.  D-Ring-Modified Analogues of Luotonin A with Reduced Planarity: Design, Synthesis, and Evaluation of Their Topoisomerase Inhibition-Associated Cytotoxicity.

Authors:  Abdulrahman I Almansour; Raju Suresh Kumar; Natarajan Arumugam; Giulia Bianchini; J Carlos Menéndez; Faruq Mohammad; Kotresha Dupadahalli; Mohammad Altaf
Journal:  Biomed Res Int       Date:  2019-11-13       Impact factor: 3.411

Review 5.  The Chemotherapeutic Potentials of Compounds Isolated from the Plant, Marine, Fungus, and Microorganism: Their Mechanism of Action and Prospects.

Authors:  Ashok K Shakya; Rajashri R Naik
Journal:  J Trop Med       Date:  2022-10-10

6.  Increasing the distance between two monomers of topoisomerase IIβ under the action of antitumor agent 4β-sulfur-(benzimidazole) 4'-demethylepipodophyllotoxin.

Authors:  Lin-Yang Sun; Li-Wen Zhu; Ya-Jie Tang
Journal:  Sci Rep       Date:  2018-10-08       Impact factor: 4.379

7.  N-thioalkylcarbazoles derivatives as new anti-proliferative agents: synthesis, characterisation and molecular mechanism evaluation.

Authors:  Maria Stefania Sinicropi; Domenico Iacopetta; Camillo Rosano; Rosario Randino; Anna Caruso; Carmela Saturnino; Noemi Muià; Jessica Ceramella; Francesco Puoci; Manuela Rodriquez; Pasquale Longo; Maria Rosaria Plutino
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

8.  Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine.

Authors:  Lindsay Reed; Radek Indra; Iveta Mrizova; Michaela Moserova; Heinz H Schmeiser; C Roland Wolf; Colin J Henderson; Marie Stiborova; David H Phillips; Volker M Arlt
Journal:  Toxicol Appl Pharmacol       Date:  2019-01-25       Impact factor: 4.219

9.  Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study.

Authors:  Edgar Márquez; José R Mora; Virginia Flores-Morales; Daniel Insuasty; Luis Calle
Journal:  Molecules       Date:  2019-12-19       Impact factor: 4.411

Review 10.  DNA topoisomerases as molecular targets for anticancer drugs.

Authors:  Kamila Buzun; Anna Bielawska; Krzysztof Bielawski; Agnieszka Gornowicz
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.